Literature DB >> 9558127

Population pharmacokinetics of vancomycin in Japanese adult patients.

M Yasuhara1, T Iga, H Zenda, K Okumura, T Oguma, Y Yano, R Hori.   

Abstract

Population pharmacokinetic parameters of vancomycin (VCM) in Japanese adult patients infected with methicillin-resistant Staphylococcus aureus (MRSA) were estimated using 1253 items of serum concentration data from 190 patients obtained in routine drug monitoring. The two-compartment linear model was adopted, and VCM clearance (CL) was correlated with the creatinine clearance (CLcr), which was observed or estimated by the Cockcroft-Gault equation. The population pharmacokinetic analysis program NONMEM with first-order conditional estimation method was used. The results showed VCM clearance to be linearly correlated with CLcr (CL [ml/min] = 0.797 x CLcr) when the estimated CLcr was <85 ml/min, but no linear relationship at higher than this level because of the lack of accuracy in the CLcr estimates. The interindividual variability of CL was 38.5%; K12 and K21 were 0.525 hr(-1) and 0.213 hr(-1), respectively. The distribution volume at steady state (V[SS]) was 60.71, with no significant dependence on the actual body weight. The interindividual variability of Vss was 25.4%. The calculated half-life (t1/2,beta) in a typical patient with CLcr of 85 ml/minute was 12.8 hours. Residual variability was 23.7%. These results were compared to those of healthy volunteers, and guidelines for dosage adjustment in VCM therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9558127     DOI: 10.1097/00007691-199804000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  33 in total

Review 1.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  N Shime; T Kosaka; N Fujita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-14       Impact factor: 3.267

3.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Authors:  Christine E Staatz; Colette Byrne; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

4.  Population pharmacokinetic and pharmacodynamic modeling of norvancomycin.

Authors:  J Zhang; Y Zhang; Y Shi; J Rui; J Yu; G Cao; J Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-09       Impact factor: 3.267

5.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 6.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

7.  Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Yusuke Tanigawara; Reiko Sato; Kunihiko Morita; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

8.  Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients.

Authors:  Anaïs Glatard; Laurent Bourguignon; Roger W Jelliffe; Pascal Maire; Michael N Neely; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

9.  Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Authors:  Ren Zhang; Ming Chen; Tao-Tao Liu; Jie-Jiu Lu; Chun-le Lv
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

10.  Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function.

Authors:  Akihiro Tanaka; Tetsuya Aiba; Takashi Otsuka; Katsuya Suemaru; Tatsuya Nishimiya; Tomoyoshi Inoue; Mitsuharu Murase; Yuji Kurosaki; Hiroaki Araki
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.